Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of decitabine in treating patients with myelodysplastic syndrome.

Key facts

Study ID

NCT00003361

Run by

Memorial Sloan Kettering Cancer Center

People needed

75

Starts

1998-04-01

Expected to finish

2009-12-01

Last updated by the study team

2013-06-26

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins Oncology Center — Baltimore, Maryland, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.